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Abstract 
Linear endobronchial ultrasound was first described in 2003.  Since that time 
the technique has spread rapidly and is now established practice in many 
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centres as the first-line mediastinal investigation for the diagnosis and staging 
of lung cancer.  In combination with endoscopic ultrasound the majority of the 
mediastinum can be assessed and this approach has been shown to have 
equivalent accuracy to surgical staging.  This strategy is also cost-effective. 
New tissue processing techniques using liquid-based thin-layer cytology and 
cell-blocks have increased diagnostic yield using immunohistochemical 
staining and molecular diagnostics. Several meta-analyses of case series and 
more recently, randomised controlled trials, have provided high-level evidence 
of efficacy leading to incorporation into national lung cancer staging 
guidelines. In addition, linear endobronchial ultrasound is increasingly used in 
the investigation of mediastinal lymphadenopathy for suspected sarcoidosis, 
tuberculosis and lymphoma.  While undoubtedly, endobronchial/endoscopic 
ultrasound has reduced the need for surgical staging in lung cancer, the latter 
still has an important role to play in certain scenarios. The challenge now 
facing clinicians is to learn to apply the appropriate test or sequence of tests 
in each patient while ensuring that operators are appropriately trained in order 
to ensure optimal outcomes.   
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
The first description of endobronchial ultrasound (EBUS) utilized a mechanical 
radial mini-ultrasound probe with a single element transducer contained within 
a polyethylene sheath passed through the working channel of a flexible 
bronchoscope[1].  Radial probe EBUS at a frequency of 20MHz provides a 
 4 
360 degree image of the airway wall and adjacent structures.  Prior to the 
advent of linear EBUS, some groups used this technique to identify the 
position of hilar and mediastinal lymph nodes prior to performing non-
ultrasound guided transbronchial needle aspiration (TBNA)[2, 3, 4]. Currently, 
the main role for radial EBUS is for localization and biopsy of peripheral lung 
nodules[5].  
 
The first report of clinical application of linear probe EBUS was published in 
Thorax in 2003[6]. In the ensuing decade the technique has progressed from 
being a research tool to gaining widespread acceptance and entering routine 
clinical practice, primarily for the diagnosis and staging of lung cancer. Linear 
EBUS utilizes an electronic curved linear array ultrasound transducer 
mounted at the distal tip of a flexible bronchoscope, which can be covered 
with a water-inflatable balloon sheath.  Several models are available, all of 
which permit simultaneous viewing of endobronchial and ultrasound imaging 
at between 5 and 10 MHz allowing tissue penetration up to 50 mm.  Real time 
transbronchial needle aspiration is performed using 21, 22 or 25 gauge 
needles through a 2 mm instrument channel.  The technique for identification 
and sampling of hilar and mediastinal lymph nodes has been described 
previously[7]. EBUS allows access to mediastinal lymph nodes 2R, 2L, 3P, 
4R, 4L, 7 and hilar nodes 10R, 10L, 11R and 11L.   
 
The mainstay of surgical mediastinal staging has been cervical 
mediastinoscopy and more recently video-mediastinoscopy.  Mediastinoscopy 
provides good access to station 2 and 4 and the upper anterior part of station 
7.  Access to lymph node stations 5 and 6, which can not be routinely 
accessed by either cervical mediastinoscopy or EBUS, is best provided by left 
anterior mediastinotomy or video-assisted thoracoscopy (VATS). Newer 
surgical techniques such as video-assisted lymphadenectomy (VAMLA) and 
transcervical extended mediastinal lymphadenectomy (TEMLA) offering 
complete lymph node dissection with reported high sensitivity and negative 
predictive value have been described but are restricted to a few specialist 
centres. 
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Indication for linear EBUS 
The main indications for linear EBUS with TBNA are: 
a. Diagnosis and staging of lung cancer 
b. Restaging of the mediastinum following neo-adjuvant chemotherapy 
c. Diagnosis of metastatic extra-pulmonary malignancy 
d. Investigation of isolated mediastinal lymphadenopathy 
i. Sarcoidosis 
ii. Tuberculosis 
iii. Suspected lymphoma 
 
A) Diagnosis and staging of lung cancer 
The first clinical studies demonstrating the utility of linear EBUS for diagnosing 
lung cancer were published as cases series between 2003 and 2006[6, 8, 9, 
10]. In 2009, a meta-analysis reported pooled sensitivity for linear EBUS-
TBNA of 0.93 (95% CI 0.91 to 0.94)[11].  More recently, Dong et al reported a 
meta-analysis of 9 studies (8 prospective), incorporating 1066 patients that 
had used EBUS-TBNA as the sole diagnostic method and for which there was 
surgical confirmation of results[12].  In this updated review, pooled sensitivity 
was similar at 0.90 [95% CI 0.84 to 0.96] and pooled accuracy 0.96.  In the 
recent American College of Chest Physicians (ACCP) 2013 guidelines[13], an 
updated systematic review by Silvestri et al incorporating 2756 patients 
revealed an overall median sensitivity of 89% (range 46%-97%).  The median 
negative predictive value in this review was 91% with an estimated disease 
prevalence of 58%.  For cervical mediastinoscopy, the ACCP 2013 review 
included 9267 patients with a sensitivity of 78% for detecting N2/3 disease. 
The sensitivity for video-mediastinoscopy was reported as 89% in 995 
patients. The first prospective controlled trial comparing EBUS-TBNA with 
(video-assisted) mediastinoscopy for mediastinal lymph node staging was 
published by Yasufuku et al (2011)[14].  In this study, EBUS was performed 
under general anaesthesia immediately prior to mediastinoscopy.  The 
sensitivity, negative predictive value and diagnostic accuracy for EBUS-TBNA 
were 81%, 91% and 93% respectively and for mediastinoscopy 79%, 90% 
and 93%.  No significant differences were found between EBUS-TBNA and 
mediastinoscopy in determining N stage.  The authors concluded that EBUS-
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TBNA might largely replace mediastinoscopy in patients with potentially 
resectable non-small cell lung cancer given similar efficacy and a lower 
complication rate.  
 
EBUS-TBNA can also be used to evaluate peri-tracheobronchial 
intrapulmonary lung masses.  Three groups have reported their experience of 
using EBUS-TBNA to diagnose intrapulmonary masses lying adjacent to a 
major airway[15, 16, 17].  In these series diagnostic sensitivity ranged 
between 82% and 94%.  Technically biopsy of such lesions can be more 
challenging as a lung mass may be composed of areas of tumour tissue along 
with areas of inflammation or fibrosis.  Therefore tissue sampling may have to 
be more extensive to maximise chances of a true positive or negative result.  
Pneumothorax has been reported as a complication in this setting but seems 
to be less than 1%.   
 
B) Re-staging of the mediastinum following neo-adjuvant chemotherapy 
Re-staging of the mediastinum following neo-adjuvant chemotherapy is 
challenging and traditionally has been undertaken using mediastinoscopy.  It 
is recognised that re-mediastinoscopy is technically more difficult to perform 
on account of adhesions and fibrotic change induced by the initial procedure 
and induction treatment. Several re-mediastinoscopy case series involving 
small numbers of patients have been reported with sensitivities for detection 
of residual disease ranging from 29-74%[18, 19, 20]. In most cases, the ‘gold-
standard’ applied has been analysis of mediastinal nodes removed at 
thoracotomy although this can only address the ipsilateral side. 
 
Few studies using EBUS-TBNA have addressed re-staging to date.  Herth et 
al, (2008) undertook a retrospective review of 124 patients with tissue proven 
Stage IIIA N2 disease who had been treated with induction chemotherapy and 
who had undergone restaging using EBUS-TBNA[21].  Surgical verification 
was performed in all cases.  The prevalence of persistent mediastinal nodal 
disease was 94%.  Sensitivity for detection of malignancy was 76% in this 
series but the negative predictive value was only 20%. Most recently 
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Szlubowski et al reported a prospective series of 106 patients undergoing 
combined endobronchial and endoscopic ultrasound for induction therapy for 
non-small cell lung cancer[22].  All patients with negative or uncertain results 
underwent transcervical extended mediastinal lymphadenectomy (TEMLA) for 
confirmation.  The prevalence of persistent mediastinal nodal disease was 
52%.  Overall, diagnostic sensitivity of endosonography for mediastinal 
metastases was 67% (95% CI 53-79), specificity 96% (95% CI 86-99) and 
overall accuracy 81% (95% CI 73-87).  The negative predictive value was 
73% (95% CI 61-83).  
 
Taken together these studies suggest that initial staging should be performed 
using endobronchial and/or endoscopic ultrasound avoiding surgical staging 
whenever possible.  Initial re-staging can also be performed using 
endobronchial and/or endoscopic ultrasound.  However, given the low 
negative predictive value of EBUS/EUS in the neo-adjuvant chemotherapy 
setting, negative findings should be confirmed by surgical staging 
(mediastinoscopy) prior to thoracotomy.   
 
C) Diagnosis of metastatic extra-pulmonary malignancy 
Mediastinal lymphadenopathy in patients with a known extra-thoracic 
malignancy is a commonly encountered problem and EBUS has been shown 
to play a useful role in determining aetiology.  In a multi-centre retrospective 
series of 161 patients, Navani et al demonstrated that EBUS-TBNA diagnosed 
mediastinal or hilar metastases in 71 (44%) of patients, new lung cancer in 20 
(12%) and sarcoidosis or a sarcoid-like reaction in 14 (9%)[23]. The final 
diagnosis prevalence for malignancy was 68%.  Using EBUS, the sensitivity, 
accuracy and negative predictive value for malignancy were 87%, 88% and 
73% respectively.  Tournoy et al also reported a sensitivity of 85% for EBUS-
TBNA of thoracic lymphadenopathy in 92 patients with extrathoracic 
malignancy[24].  
 
D) Investigation of isolated mediastinal lymphadenopathy 
Identification of isolated mediastinal lymphadenopathy by CT is a common 
clinical scenario and prior to the advent of EBUS, was normally investigated 
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using a thoracic surgical approach, most commonly cervical mediastinoscopy 
or VATS.  The role of EBUS for investigation of isolated mediastinal 
lymphadenopathy has been described by several groups but for simplicity is 
reviewed here by disease category.   
 
i) Investigation of suspected sarcoidosis 
Historically, the standard bronchoscopic investigation for patients suspected 
of having sarcoidosis has been flexible bronchoscopy with endobronchial and 
transbronchial lung biopsies.  Since 2007, several groups have reported their 
experience of using EBUS-TBNA for assisting the diagnosis of sarcoidosis.  A 
recent systematic review and meta-analysis by Agarwal et al identified 15 
good quality, predominantly prospective studies involving 553 patients[25].  
The diagnostic yield of EBUS-TBNA ranged from 54-93% with pooled 
diagnostic accuracy of 79% (95% CI 71-86%).  Diagnostic yield was noted to 
be significantly higher in the prospective studies compared with retrospective 
studies. Of note, the diagnostic yield of EBUS-TBNA surpassed that of 
traditional bronchoscopic biopsy techniques.  Combining EBUS-TBNA with 
transbronchial lung biopsy and/or endobronchial biopsy should increase 
diagnostic accuracy yet further.  The first randomized controlled trial to 
compare the diagnostic accuracy of EBUS-TBNA with transbronchial biopsy in 
patients with suspected sarcoidosis was reported by von Bartheld et al[26].  
Three hundred and four consecutive patients with suspected stage I/II 
pulmonary sarcoidosis underwent either bronchoscopy with transbronchial 
and endobronchial lung biopsy or endosonography (EBUS-TBNA or EUS-
FNA).  Bronchoalveolar lavage was performed in all patients.  Overall the 
diagnostic yield to detect granulomas using endosonography (80%) was 
significantly higher than using bronchoscopy with transbronchial biopsy 
(53%).  
 
ii) Mycobacteria Tuberculosis 
To date, few studies have examined the role of EBUS-TBNA for the diagnosis 
of tuberculous intrathoracic lymphadenopathy.  In a multi-centre study, Navani 
et al examined the diagnostic sensitivity of EBUS in 156 patients with a final 
clinical diagnosis of M tuberculosis[27].  EBUS-TBNA led to a diagnosis of M 
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tuberculosis in 94% of cases.  Pathological findings were consistent with TB in 
86% of cases and in 47% a positive culture of M tuberculosis was obtained.  
In another series of 59 patients undergoing investigation for suspected M 
tuberculosis, of the 41 with a final confirmed diagnosis, pathological findings 
were consistent with TB in 80% but in only 27% were acid-fast bacilli 
seen[28].  Of the 37 cases put up for culture, 17 (46%) were positive.  The low 
positive culture rates are likely to represent the relatively low bacillary load in 
intrathoracic tuberculous lymph nodes and the yield obtained with EBUS in 
this series is similar to that reported using other modalities such as 
mediastinoscopy and endoscopic ultrasound guided biopsy. Overall, EBUS-
TBNA appears to be a useful first-line investigation in patients suspected of 
having M tuberculosis.   
 
iii) Investigation of suspected lymphoma 
The role of EBUS-TBNA in the diagnosis and management of lymphoma is 
unclear. Retrospective studies have shown varying sensitivities from 57-91%.  
Kennedy et al, in a retrospective review of 25 patients who underwent EBUS-
TBNA for intra-thoracic lymphadenopathy of uncertain cause, demonstrated 
that 10 of the 11 patients with a final diagnosis of lymphoma were correctly 
identified giving a sensitivity of 90.9% and a specificity of 100%[29].  In a 
recent retrospective study reviewing 65 patients with a new diagnosis of 
lymphoproliferative disease who had undergone EBUS, Iqbal et al found the 
sensitivity for a definitive diagnosis of lymphoma was only 38%; 22% in cases 
of new diagnosis and 55% for patients with recurrent disease[30].  While a 
presumptive diagnosis of lymphoproliferative disease may be established by 
EBUS using a combination of cytopathology and flow cytometry, a surgical 
biopsy is often required to confirm a specific histological subtype and/or 
grade.  This issue was highlighted in a study by Steinfort et al who used 
EBUS-TBNA in 55 patients with isolated mediastinal lymphadenopathy[31].  
Non-diagnostic cases underwent surgical biopsy or radiological follow-up.  A 
final diagnosis of lymphoma was made in 16 patients.  However, of these, a 
further surgical biopsy was required in 4 patients for tumour classification.  In 
another 5 cases, surgical biopsy revealed lymphoma following a non-
diagnostic EBUS-TBNA.  Although a diagnostic sensitivity rate of 76% was 
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reported, this becomes 57% when adjustment is made for cases that required 
surgical biopsy for definitive diagnosis.  
 
More recently, a retrospective study by Moonim et al reported a sensitivity of 
89% in 100 patients with mediastinal lymphoma[32]. The patient cohort 
included new diagnoses and relapsed cases. Rapid-on site pathology was 
used to target lymph nodes with the most cellular aspirates, and a relatively 
high number of passes were made, mean 6.7 per lymph node for cases of 
Hodgkin lymphoma. The cytopathology results were independently reviewed 
by the institution’s haemato-oncology team, and further tissue sampling, 
largely with mediastinoscopy, was deemed necessary in 28 of 100 cases. 
There was 93% concordance between paired EBUS-TBNA and histology 
samples.  While this study does support the use of EBUS-TBNA as an initial 
diagnostic tool in suspected de novo or recurrent lymphoma it should be 
recognized that it was undertaken by an expert group working closely with 
lymphoma pathologists and a lymphoma multi-disciplinary team.  
 
 
Although the current British Thoracic Society guidelines do not recommend 
the use of EBUS for diagnosis of de novo cases of lymphoma, recent reports 
suggest that EBUS may have an important role to play in this setting and a re-
evaluation of the current guidance through carefully designed prospective 
studies would be timely. In the mean time, although surgical biopsy remains 
the initial diagnostic procedure of choice, close liaison between 
bronchoscopists, thoracic surgeons and the lymphoma MDT is recommended 
to achieve the optimal approach to diagnosis. 
 
 
Adequacy of EBUS-TBNA aspirates for subtyping and genotyping lung 
cancer 
The development of novel agents designed to selectively target molecular 
pathways in the last few years has meant that it is increasingly important for 
pathologists to have sufficient material for subtyping and genotyping lung 
cancer.  At the same time the increasing use of minimally invasive sampling 
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techniques such as EBUS and EUS has resulted in the provision of smaller 
fine needle aspirate samples.  In order to address these issues new tissue 
processing techniques using liquid-based thin-layer cytology and cell blocks 
have been developed[33]. These approaches have increased diagnostic yield 
and provide material for immunohistochemical staining.  Although there have 
been concerns that fine-needle aspirate cytology samples might not provide 
sufficient material for subtyping and genotyping this has not proved to be the 
case.  In a large series involving 774 patients, Navani et al showed that 
accurate subtyping of EBUS-TBNA samples was possible in 77% of cases 
and genotyping for EGFR mutations was possible in 90% (107 of 119 
cases)[34].  In another series of 42 lung cancer patients diagnosed with 
EBUS-TBNA, overall success rate for EGFR mutation analysis was 95%, 
KRAS mutation 90.5% and ALK 90.5%[35].  These are similar values to those 
that can be obtained with histological biopsies.  
 
Endoscopic Ultrasound 
Linear Endoscopic Ultrasound (EUS) is similar to endobronchial ultrasound 
albeit using an oesophageal approach. EUS can be used to evaluate lymph 
nodes lying to the left side of the trachea and in the inferior/posterior 
mediastinum – stations 2L, 4L, 7, 8 and 9.  The latter two groups are not 
accessible from the airway.  In addition, the left adrenal gland can be 
assessed and biopsied as can the left lobe of the liver and the coeliac lymph 
nodes.   
 
Combined Endobronchial and Endoscopic Ultrasound 
Endobronchial and endoscopic ultrasound can be performed together under 
local anaesthetic and sedation.  In combination, the entire mediastinum, with 
the exception of station 5 and 6 lymph nodes, can be assessed as well as 
hilar lymph node stations (10 and 11) along with the left adrenal, left lobe of 
liver and coeliac nodes.  In practice the dual procedures are generally well 
tolerated and can be performed back-to-back by an experienced team in 
about 50 minutes.  
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Annema and colleagues performed the first randomised controlled trial 
comparing combined endobronchial and endoscopic ultrasound with surgical 
staging (ASTER trial)[36].  In the EBUS/EUS arm cases that were negative for 
malignancy were referred for surgical staging, usually mediastinoscopy, prior 
to thoracotomy.  In the endoscopic arm the sensitivity for detection of 
malignancy was 85%, which was not significantly different to 79% in the 
surgical arm.  The addition of mediastinoscopy in the case of a negative 
EBUS/EUS, increased sensitivity to 94%.  However, this 9% increase in 
sensitivity translated into the need for 11 mediastinoscopies in order to 
identify one patient with mediastinal nodal metastasis.   
 
In practice, this study has shown that a combined EBUS/EUS performed by 
experienced operators has similar sensitivity to surgical staging.  Although 
some commentators recommend that all negative EBUS/EUS examinations 
are referred for surgical staging prior to thoracotomy, some experienced 
endosonography teams only refer patients where clinical suspicion of 
mediastinal disease remains high.  
 
Endobronchial and Endoscopic Ultrasound using the endobronchial 
ultrasound bronchoscope 
Some groups now perform combined EBUS and EUS using an EBUS 
bronchoscope. Hwangbo et al, 2010 investigated 150 consecutive patients 
with potentially operable (suspected) NSCLC requiring mediastinal 
staging[37].  The sensitivity, negative predictive value and diagnostic 
accuracy of EBUS-TBNA for the detection of mediastinal metastases were 
84%, 93% and 95% respectively.  Performing EUS with an EBUS 
bronchoscope (termed EUS-B) to assess nodal stations inaccessible by 
EBUS improved these outcomes to 91%, 96% and 97% respectively. While 
there are advantages to performing EUS with an EBUS bronchoscope in 
terms of financial investment, operating costs and investigation time, there are 
also limitations.  The EBUS scope does not permit the scanning range and 
ultrasound penetration depth afforded by the EUS scope and the ultrasound 
quality is also inferior due to the smaller transducer.  In practice, anatomical 
orientation within the mediastinum can be more challenging and aspiration of 
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lymph nodes can be more difficult as the EBUS scope provides a less stable 
platform during fine needle aspiration than a conventional EUS endoscope.  
 
To assess the best approach to mediastinal staging using EBUS and EUS-B, 
Kang et al randomized patients to an EUS-centred approach in which EUS-B 
was performed initially, followed by EBUS or to an EBUS-centred approach 
during which EBUS was performed initially followed by EUS-B. While adding 
EUS-FNA to EBUS-TBNA did not significantly increase the accuracy or 
sensitivity of detecting mediastinal metastases, adding EBUS-TBNA to EUS-
FNA increased the accuracy from 86.5% to 97.3% (p=0.016) and sensitivity 
from 60.0% to 92.0% (p=0.0080)[38]. These results suggest that commencing 
mediastinal staging with EBUS-TBNA and adding EUS-FNA, in selected 
cases, may be the most efficacious approach.   
 
Cost effectiveness of endosonography 
To date, there have been few studies examining the cost-effectiveness of 
endosonography and/or mediastinal staging. Previous work has been based 
on retrospective data and has used decision analysis approaches to produce 
models of possible outcomes and applied cost-minimisation analysis in order 
to determine the most economical health care strategy among various 
alternatives[39, 40]. The recently published 2011 NICE guideline for lung 
cancer diagnosis and treatment includes an economic model for a number of 
potential diagnostic pathways[41].  In the absence of empirical evidence the 
model was largely based on expert opinion.  Sharples et al have recently 
reported survival, quality of life and resource use for patients in the ASTER 
trial from a UK perspective[42].  Cost-effectiveness using economic methods 
predominant in the UK showed that the endosonography strategy was 
cheaper and patients had better quality of life during staging.  In recognition 
that health economic methodology varies substantially between different 
countries, Rintoul et al undertook country-specific cost effectiveness 
analysis[43].  In all three countries, the endosonography strategy had slightly 
higher quality-adjusted life years over 6 months and was cheaper.  Taking the 
clinical, quality of life and cost-effectiveness data together the authors 
concluded that mediastinal staging should commence with endosonography.   
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Complications 
EBUS-TBNA is regarded as a safe technique with a good safety profile.  
Major complications related to EBUS-TBNA are rare. For the most part, 
complications are minor and similar to those of standard videobronchoscopy - 
cough, hypoxaemia and self-terminating post-procedure pyrexia.  In their 
meta-analysis, Gu et al (2009) reported only two complications in 1299 
procedures (0.15%)[11]. As the number of procedures being performed 
globally has risen in the last few years, case reports of more serious 
complications including pneumothorax, clinically significant airway injury, lung 
abscess, mediastinitis, haemopneumomediastinum have been published.  
One procedure-related death has been reported due to a post-procedure 
streptococcal septicaemia likely caused at intubation as a result of 
nasopharyngeal carriage[34]. A recent study reviewing complications in 190 
studies totalling 16,181 cases of EUS or EBUS reported a serious adverse 
event rate of 0.05% for EBUS and 0.3% for EUS although the authors state 
that they suspect that complications are often under-reported[44]. A recent 
prospective registry study evaluating 1317 EBUS-TBNA cases showing a 
complication rate of 1.44% would support this assertion[45].  
 
Training, Implementation and Service Provision 
Over the last ten years EBUS has spread rapidly among respiratory 
physicians and thoracic surgeons. As with many new techniques, initial 
publications come from a small number of groups who gain early expertise 
and EBUS is no exception.  There is always a risk with any complex 
procedure requiring manual dexterity and hand-eye co-ordination that the 
‘headline’ outcomes in terms of published diagnostic sensitivity and accuracy 
are not achieved by all and that the technique looses credibility as it is 
practised more widely.  Therefore, some form of training requirement and on-
going competency assessment will be required.   
 
To date, relatively little has been published about the learning experience of 
EBUS-TBNA.  Several groups have commented on their ‘learning curve’ 
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within reports about their initial experiences of using EBUS-TBNA[46, 47].  
The most systematic evaluation by Kemp et al[48], undertook CUSUM 
analysis on the first 100 procedures performed by five experienced 
bronchoscopists learning EBUS-TBNA. This showed that despite extensive 
bronchoscopy experience there was quite marked variation in length of time 
before competence in EBUS-TBNA was achieved.  At present there are no 
specific guidelines on training required either in terms of education or number 
of cases to be performed.  In practice, many learners attend a dedicated 
course about EBUS-TBNA and visit an experienced centre to observe cases 
or practice on a virtual reality simulator.  An EBUS Skills and Tests 
Assessment Tool is available[49].  To date many national societies have 
avoided stipulating a specific number of procedures to be performed before 
an individual is deemed competent as such numbers are often arbitrary and 
rather the focus should be on monitoring an individual’s performance and 
outcomes.  However, the skill level required for fully assessing and accurately 
staging the mediastinum including biopsying FDG-avid sub-centimetre nodes 
to achieve a high negative predictive value is very different to that required for 
biopsying a large subcarinal lymph node mass for diagnostic purposes only.  
In order to achieve and maintain high levels of competence it is likely that 
EBUS-TBNA will be confined to larger centres specialising in lung cancer and 
interventional bronchoscopy.   
 
 
Conclusion 
Over the last decade, the advent of EBUS (and EUS) for the assessment of 
mediastinal disease has had a huge impact and the technique has been 
incorporated into many major clinical guidelines[13, 41, 50, 51]. The challenge 
facing clinicians now will be to learn to apply the appropriate test or sequence 
of tests for each patient while ensuring that the technique is practised to 
uniformly high standards.  While endosonographic techniques can answer 
many questions, surgical staging will continue to have an important role to 
play in certain scenarios such as the diagnosis of lymphoma, mediastinal 
restaging and when there is dubiety following a negative endosonographic 
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result.  Close working between endosonographers, pathologists and thoracic 
surgeons within the multi-disciplinary team will be essential to optimise the 
outcome for every patient.   
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